Daniel Heller, PhD is an Assistant Member of Molecular Pharmacology at Memorial Sloan Kettering Cancer Center. Dr. Heller has created a nanotechnology platform that would allow doctors to develop personalized medicines that target the many mutations in a specific patient’s tumor while steering these drugs away from healthy cells to avoid toxicity. His research will extend beyond the traditional limits of nanomedicine by looking at the specific changes in drug pharmacology that are needed to improve kinase inhibitors, a common component of chemotherapy that can cause severe side effects.
